Premium
Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis
Author(s) -
Ananth Prasanna,
Werger Annette,
Voss Stephan,
RodriguezGalindo Carlos,
Janeway Katherine A.
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26375
Subject(s) - medicine , doxorubicin , fibromatosis , aggressive fibromatosis , chemotherapy , retrospective cohort study , oncology , pediatrics , surgery
Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression‐free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.